For example, and as described above, atezolizumab (an immunotherapeutic agent targeting PD‐L1) in combination with bevacizumab (an inhibitor of VEGF‐A) has been found to offer improvements in OS and PFS vs sorafenib, in patients with unresectable HCC, who had not received prior systemic therapy.14 This evidence concerns the gene VEGFA and hepatocellular carcinoma.